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Introduction: Bony metastases in cervical carcinoma are rare; however, autopsy studies indicate that they are underdiagnosed. A
retrospective study was undertaken to describe the risk factors and tumour characteristics and estimate the prevalence of bone
involvement in women with cervical cancer at a tertiary institution in South Africa.
Methods: A retrospective cohort analysis of women with cervical cancer diagnosed between 2014 and 2015 was undertaken.
Demographic, treatment and follow-up data were collected for all women with bone metastases confirmed by imaging.
Descriptive statistics were generated.
Results: The study identified 642 patients with cervical carcinoma, of whom 25 (3.89%) were diagnosed with bone involvement.
Ten women had bone involvement at diagnosis and 15 women at recurrence, occurring a median of 286 days after primary
treatment. Survival after the diagnosis of bone metastases was short, with 88% of patients dying within six months. The
WHO performance status score at diagnosis was a significant predictor of survival (p = 0.024). A prognostic score was utilised
and those with a high score had a significantly shorter survival (median 61 days) than those with a low score (median 158
days) (p = 0.0065).
Conclusions: Although bone metastases are rare in women with cervical cancer, they are important to recognise. Healthcare
workers should be vigilant regarding increased analgesic use and chronic pain, as these may indicate bone involvement. As
survival is short, a prognostic score is valuable in tailoring treatment. A patient’s quality of life may be greatly improved by
an appropriate radiotherapy and palliative care plan.
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Introduction
Cervical cancer is the second most common cancer in women
after breast cancer in sub-Saharan Africa.1 Many women in
South Africa present with late-stage disease, due to poor
access to the cervical screening programme and lack of knowl-
edge regarding the disease.2 Metastases to bone or direct infil-
tration of cancer into bone, although rare, are important to
recognise, as palliative radiotherapy treatment can then be time-
ously employed to relieve pain and improve quality of life. As
survival after the diagnosis of bone involvement is short, an
appropriate palliative care plan should be tailored according
to the patients’ limited prognosis.
The prevalence of bone metastases ranges from 1.8% to 6.6%
(average 4.6%) in a review including 4 422 patients.3 Two
South African studies, the first of radiographic findings on 1
347 women at cervical cancer diagnosis at Johannesburg
General Hospital and the second at Tygerberg Hospital, investi-
gating the detection of bone metastases by bone scan in 540
patients, gave prevalences of bony involvement at diagnosis
of 4.6% and 2.03% respectively.4,5 A higher rate of bone involve-
ment was reported at an autopsy study in all gynaecological
cancers.6 Of the 112 cervical cancer patients who were autop-
sied, 20 (17.9%) were found to have bony involvement. Of
these only seven (6.3%) had pre-morbid radiographic evidence
of bone metastasis, indicating that it is likely underdiagnosed.
The risk of developing distant metastases after chemoradiation
for cervical cancer was investigated by Schmid et al.7 The
most important factors were lymph node involvement and Inter-
national Federation of Gynaecology and Obstetrics (FIGO) stage
of disease. In total, 11% of patients staged Ib to IIIa with negative
nodes developed distant metastases, while 38% of patients
staged IIIb to IVa or with positive nodes developed distant
metastases. In the group with positive nodes, the number of
chemotherapy cycles given during radiation was also related
to the risk for developing distant metastases.7 Poorly differen-
tiated tumours and histological types other than squamous car-
cinoma, such as neuroendocrine, clear cell and adenoid cystic
carcinoma, were found to have a greater tendency to spread
to bone in a retrospective study.3
Matsumiya et al. investigated factors that influence survival after
the detection of bone metastases from cervical cancer. After
multivariate analysis, five factors proved to be significant: syn-
chronous extraskeletal metastasis; World Health Organization
(WHO) performance status; onset time at initial presentation
(at diagnosis or recurrence); multiple bone metastases; and a
bone metastasis-free interval of less than 12 months. They
used these five factors to develop a prognostic scoring system,
where one point was allocated for each significant factor. The
6-month survival in patients with a score of 2 was 61.4%. For
those with a score ≥ 4, the 6-month survival was 12.5% and
the median survival was 13 weeks.8 This information is very
helpful in planning treatment, especially when it comes to
spinal surgery for bone metastasis, where a 3–6-month life
expectancy is a prerequisite.
Radiotherapy has been shown to be an effective palliative treat-
ment for bone pain due to metastatic cancer.9 A Cochrane
review included 3 435 patients and investigated the efficacy of
single-fraction radiotherapy in comparisonwithmultiple-fraction
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radiotherapy for relieving bone pain. Complete pain relief was
reported in one-third of patients, with partial relief in 60% of
patients, with no difference in efficacy between single-fraction
and multiple-fraction regimes.10
Life expectancy after the development of bone metastases from
cervical cancer is short, with 95% of patients dying within two
years. It is important to identify risk factors that may reduce
life expectancy, so that the treatment offered is of an appropri-
ately short duration and offers maximal palliation. This study
aimed to study patients with bone metastases from cervical
cancer at Tygerberg Hospital Gynaecologic Oncology Unit in
order to identify common risk factors and tailor a more suitable
follow-up schedule for those who are at high risk.
Methods
This study is a cohort analysis of folders of patients with con-
firmed cervical cancer who attended the Tygerberg Gynaecol-
ogy Oncology Unit for their initial visit between January 2014
and December 2015. Patients were identified from the gynaeco-
logical-oncology records, which were assessed for imaging
studies confirming bone metastases.
Patients were initially clinically staged, with basic imaging
including chest X-ray, abdominal ultrasound and a cystoscopy.
A CT scan was used for planning radiotherapy fields. The stan-
dard protocol of 45–50 Gy to the pelvis with concomitant
weekly cis-platinum, followed by 25 Gy given as brachytherapy,
was offered to patients who were treated with curative intent.
This protocol was modified for patients who were treated with
palliative intent. Follow-up consisted of a clinical examination,
and specific investigations based on the patient’s symptoms,
every three months for the first two years, six-monthly for the
next three years and then yearly. Data were censored on
January 15, 2018.
Descriptive statistics, means, medians and ranges were reported.
Means were compared using the t-test with significance set at
0.05. Kaplan–Meier estimates were used for survival analysis
and survival curves were compared using the rank-log
method. Statistics were analysed using Social Science Statistics
(http://www.socscistatistics.com), and the Real Statistics
Resource Pack software, Release 5.4 (www.real-statistics.com)
in Microsoft Excel 2010 (Microsoft Corp, Redmond, WA, USA),
was used to generate the Kaplan–Meier estimates.
The study was approved by the University of Stellenbosch
Health Research Ethics Committee (reference number S17/10/
258). The patients’ names and any identifying characteristics
remained confidential throughout the study.
Results
A total of 642 newly diagnosed cervical cancer patients attended
the Gynaecological Oncology Unit between January 1, 2014 and
December 31, 2015. Of these, 25 patients (3.89%) were found to
have radiological evidence of bone involvement. The mean age
of women with bone metastases was 46 years (SD 11.28; range
25 to 63 years). Six women were found to have bone involve-
ment at initial staging and four women at imaging during radio-
therapy treatment planning. The remaining 15 patients had
bone metastases at recurrence. Their clinical details are given
in Tables 1 and 2.
Pain was the main complaint in 24 out of 25 patients with bone
involvement. In addition, four women had neurological
symptoms, including lower limb weakness and urinary retention
due to spinal cord compression. One patient was found to have
a clavicular metastasis on FDG-PET scan and was asymptomatic.
The commonest sites of bony involvement were the pelvic
bones (n = 9), lumbar spine (n = 9), thoracic spine (n = 7),
sacrum (n = 5) and ribs (n = 4). The distribution of sites is
shown in Figure 1. Thirteen patients had multiple bone
metastases.
All three patients with neuroendocrine cervical tumours and one
patient with glassy cell type squamous carcinoma had bony
involvement and extraskeletal metastases at cervical cancer
diagnosis. The histology of the tumour in the remaining 21
patients was a moderately to poorly differentiated squamous
cell cervical carcinoma.
With regard to imaging modalities, four patients were diagnosed
with bone involvement on plain X-ray and one on bone scan.
Nine women had bone metastases found on FDG-PET scan, six
on CT and five on MRI. At the time of diagnosis of bony involve-
ment only three patients had no other metastases. The other
22 patients all had metastases in multiple organs including
lung (n = 15), lymph nodes (n = 18), liver (n = 7), brain (n = 1),
bladder (n = 2) and local recurrence in the pelvis (n = 3).
In those patients who had bony involvement at cancer recur-
rence, the time from presentation at the oncology clinic to the
time of diagnosis of bone metastases was a median of 366
days (136–520 days). The time from the end of primary treat-
ment to the diagnosis of bone involvement was a median of
286 days (3–436).
In all patients the time from diagnosis of bone involvement to
death was a median of 80 days (6–331 days). Patients with
bone involvement at cervical cancer diagnosis survived for a
median of 66.5 days (30–167 days) and patients with bone invol-
vement at recurrence survived for a median of 85 days (6–331
days) after bone involvement was diagnosed. Although survival
was shorter in those with bone involvement at diagnosis the
means were not significantly different (p = 0.242).
Sixteen patients (64%) died within 3 months of diagnosis of
bone involvement and 22 women (88%) died within 6 months.
All patients had died by 11 months. The survival curve is
shown in Figure 2.
Twelve patients had a single bone metastasis and survived for a
median of 126.5 days (36–286 days) after diagnosis of the bone
involvement. Multiple bone metastases were identified in 13
patients with a median survival of 71 days (6–331 days). A com-
parison of means was not statistically significant, but trended
towards better survival in the patients with a single bone metas-
tasis (p = 0.094).
Extraskeletal metastases were found in 22 patients with amedian
survival of 78 days (6–331 days). Three patients had no extraske-
letalmetastaseswith amedian survival of 158 days (78–168 days).
The means were not significantly different (p = 0.52).
The WHO performance status was documented in 17 patients.
Eight women had a performance status of 1–2 with a median
survival of 148 days (39–286). Nine women had a performance
status of 3 or 4 with a median survival of 72 days (6–168
days). The t-test for comparison of means was statistically signifi-
cantly different (p = 0.024).
32 Southern African Journal of Gynaecological Oncology 2019; 11(2):31–37
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X-ray Analgesia 39 40
7 34 III b SCC Left acetabulum Lung, liver, LN PET RT
10 Gy 1#
167 413
8 51 III b SCC Left clavicle Lung, liver, LN PET Analgesia 50 102
9 62 III b Lumbar vertebrae Lung Bone scan RT
20 Gy 5#
80 94






































11 39 II b SSC Ilium, sacrum, thoracic
spine, rib
Liver, LN PET RT
6 Gy 1#
300 331 767
12 57 II b SCC Thoracic vertebrae Lung CT RT
8 Gy 1#
319 36 484
13 25 III b SCC Right acetabulum Lung, LN PET Analgesia 171 115 419
14 63 III b SCC Sacrum, lumbar spine Lung, liver, LN CT Analgesia 406 86 645
15 50 II b SCC Thoracic spine, lumbar
spine
Lung, pelvis MRI RT
8 Gy 1#
436 6 540
16 60 III b SCC Cervical spine, rhoracic
spine, lumbar spine
Lung, LN MRI RT
20 Gy 5#
63 72 274
17 45 II b SCC Ilium Lung, LN PET RT
15 Gy 5#
299 286 664
18 56 III b SCC Lumbar spine None X-ray Analgesia 286 78 461
19 35 II b NET Lumbar spine, skull LN PET RT
8 Gy 1#
88 32 287
20 55 III b SCC Cervical spine, thoracic
spine, ribs, scapula,
mandible
Lung, LN PET RT
12 Gy 3#
203 71 379
21 54 III b SCC Acetabulum, rib Pelvis, LN PET RT
15 Gy 5#
369 76 535
22 42 III b SCC Ilium Bladder, LN MRI Analgesia 145 85 316
23 49 IV b SCC Lumbar spine Lung, liver, LN,
ovaries
CT Analgesia 3 138 353
24 41 III b SSC Lumbar spine None X-ray RT
20 Gy 5#
113 168 435
25 39 II b SSC Lumbar spine LN CT Chemo 427 245 769
Median/
mean
47.3 286 85 461










Nine patients with recurrence had a bone metastases-free inter-
val of more than 6 months after the end of primary cervical
cancer treatment with a median survival after recurrence of 78
days (6–331 days). In 6 patients the bone metastases-free inter-
val was less than 6 months with a median survival of 100 days
(32–168 days) which was not significantly different (p = 0.529).
Table 3 shows the comparison of means for the different prog-
nostic parameters.
A scoring system with one point given for each of primary
bone involvement at diagnosis, multiple bone metastases,
extraskeletal metastases and performance status 3 or 4 was
assigned for the 17 patients with all these parameters docu-
mented. Nine patients had a score of 1–2 with a median
Figure 1: Distribution of bone metastases.
Figure 2: Kaplan–Meier survival after the diagnosis of bone metastases.
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survival of 158 days (36–286 days) and eight patients had a
score of 3–4 with a median survival of 61 days (6–117 days).
Survival was significantly better for those with a low score
(p = 0.0065). The survival curve demonstrating this significance
in survival is shown in Figure 3. The p-value for the log-rank
test = 0.0072, again confirming that these survival curves are
significantly different.
Seventeen patients received radiation therapy for bone involve-
ment. Of these, nine patients received a single fraction with a
dose ranging from 6 Gy to 10 Gy, with most receiving 8 Gy. Six
patients received 3–5 fractions (12–20 Gy in total). Three of
these patients had spinal metastases with neurological deficit
and one had a recurrence in the external iliac nodes with infiltra-
tion of the iliac bone and a good performance status. Two
patients, who had sacral involvement at cancer diagnosis,
received higher doses of radiation to treat both the primary
disease and the bone involvement. One patient received che-
motherapy for an in-field recurrence. Five patients, most of
whom had multiple extraskeletal metastases, received only
analgesics. Two patients did not attend for treatment of bone
metastases. There was no difference in mean survival between
those who received radiation therapy and those who did not
(p = 0.544).
Of the 15 patients with bone involvement at recurrence, 6
patients had received radical radiotherapy (46–50 Gy) for their
primary tumours with 4–5 cycles of concomitant weekly cis-
platinum (40 mg/m2). A further six patients received radiother-
apy, but with only one or no cycles of cis-platinum, due to
renal impairment. There was no significant difference in the
time from end of primary treatment to the development of
bone metastases in these two groups (p = 0.356). The patients
who did not receive cis-platinum developed more multiple skel-
etal metastases (four of six patients) and all had extraskeletal
metastases at recurrence.
Discussion
In this study, 3.89% of patients diagnosed with cervical cancer
developed bone metastases or had direct bony infiltration.
The median time from presentation with cervical cancer to the
diagnosis of bone metastases at recurrence was 366 days
(136–520 days). In a study by Ratanatharathorn et al., 75% of
patients had developed bone metastases within 36 months of
cervical cancer diagnosis and 87.9% of patients within 5
years.3 In a Japanese study, 85% of patients with bone metas-
tases were diagnosed within 2 years after completing treat-
ment.11 The median time from diagnosis of cervical cancer to
diagnosis of bone metastases in a study by Thanapprapasr
et al. was 16 months and by Yoon et al. was 27 months.12,13 As
our follow-up time was limited to four years it may be that we
have identified only about 80% of patients who will develop
bone metastases, and this would explain why our prevalence
is lower than the reported literature (4.6%). Although not quan-
tified in this study, a high loss to follow-up of women with
cancer is observed at our unit.
There were fewer patients with bone involvement at diagnosis
(1.56%; 10/642 patients) than previously reported at Tygerberg
Hospital (2.03%) or at Johannesburg General Hospital (4.6%).4,5
These are both historical studies published prior to the
implementation of routine 10-yearly Papanicolaou smears in
South Africa and this could partly be the reason why women
in these earlier studies presented with more advanced disease.
As in most studies, pain was the most common symptom of
bone involvement in 24 of 25 patients. Four patients had associ-
ated neurological symptoms. Similarly, Thanapprapasr et al.
reported 37 of 41 patients with pain as the presenting com-
plaint, and 5 of 41 women with neurological deficit.12 In a
pooled analysis of over 5 500 patients with bone metastases
from various cancers, the authors showed that pain and strong
opioid use were significantly increased prior to a skeletal-
related event such as a pathological fracture or spinal cord com-
pression.14 It is of importance therefore to monitor analgesic use
carefully during follow-up visits as an increase may indicate a
bone metastasis or skeletal-related event.
Over 60% of bone metastases from cervical cancer occur in the
spine, most commonly the lumbar spine (36.4–51.9%). Multiple
bone metastases are diagnosed in over 50% of patients.8,13
The findings in this study are similar, with 70% of metastases
occurring in the spine (35% in the lumbar spine) and multiple
skeletal metastases diagnosed in 52% of patients.
At the time of diagnosis of bone involvement only three (12%)
patients had no extraskeletal metastases. Coexisting metastases
most commonly occurred in the lungs and lymph nodes. Extra-
skeletal metastases were similarly common in 92.6% (50/54) of
patients as reported by Matsumiya et al., 78% (32/41) reported
by Ratanatharathorn et al. and 53.6% (22/41) patients in a
study done by Thanapprapasr et al.3,8,12 The most common
sites for extraskeletal metastases in all studies were lungs,
lymph nodes and liver. If a skeletal metastasis is identified at
diagnosis or at recurrence it is important to consider further
imaging, as more than 50% of patients will have coexisting
extraskeletal metastases.
Skeletal metastases at recurrence were diagnosed a median of
366 days (12 months) after diagnosis of cervical cancer and a
median of 286 days (9.5 months) after the end of treatment.
This is a shorter time than in other studies.12,13
In the study by Yoon et al., patients with early stage disease had
a median of 22 months from cervical cancer diagnosis to devel-
opment of bone metastases, while patients with advanced stage
cervical cancer had a median time of 15 months.13 There were
no patients with early-stage cervical cancer in our study
cohort,which explains the short duration to development of
bone involvement. Survival after the diagnosis of bone
Figure 3: Kaplan–Meier survival curves comparing prognostic scores. (A)
Prognostic score 1–2. (B) Prognostic score 3–4. Scores according to Mat-
sumiya et al.8
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metastases is short. In this study 88% (22/25) of patients had
died by six months after diagnosis of bone involvement and
all patients had died by 11 months. This is consistent with
other studies. Ratanatharathorn et al. reported a median survival
of 3.5 months, Matsumiya et al. a median survival of 5 months,
and Thanapprapasr et al. and Yoon et al. reported a median sur-
vival of 7 and 10 months respectively.3,8,12,13
Matsumiya et al. identified a number of independent factors that
were associated with a poorer survival and devised a prognostic
scoring system.8 When these parameters were analysed in our
cohort, performance status was the only significant factor. The
bone metastasis-free interval < 12 months was not applicable
to 10 patients with bone involvement at diagnosis and there-
fore, to apply the prognostic score to our whole cohort, this par-
ameter was omitted. A score of 3–4 was significantly predictive
of poor prognosis compared with patients with a score of 1–2
(p = 0.0065). Although our cohort was too small to run multi-
variate analysis for the different factors, this scoring system
has previously been validated in a larger study. Its use is valuable
in planning treatment, especially in patients presenting with
bone involvement at diagnosis where, if a lengthy treatment is
planned, patients with a poor prognostic score may die before
completing radiation. It is also important for counselling the
patient and family regarding survival and in arranging a pallia-
tive care plan.
Conclusions
Although bone metastases are rare, patients with advanced
disease, lymph node involvement and non-squamous histology
are at higher risk. Most recurrences, including bone metastases,
occur in the first two years of treatment. Healthcare providers
should be vigilant during follow-up to identify symptoms such
as persistent pain or increased analgesic use in order to diag-
nose bone metastases as early as possible. After the diagnosis
of bone involvement has been made, performance status
should be documented, as this was the most predictive par-
ameter of survival in our study. A prognostic score should be cal-
culated to guide further radiotherapy treatment and for
counselling of the patient and family. The use of bisphospho-
nates needs to be considered, but further studies regarding
their use in patients with cervical cancer need to be undertaken.
Although radiotherapy has not been shown to improve survival,
a single 8 Gy fraction is very effective in palliating pain from
bone infiltration.
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